Chemotherapy in thymic neoplasms

Pier Franco Conte, Fausto Barbieri

Research output: Chapter in Book/Report/Conference proceedingChapter


Thymic neoplasms are chemotherapy-sensitive tumors with a 30-50% 5-year survival in previously untreated patients. Responses in small series have been reported with single-agent doxorubicin, cisplatin, etoposide, ifosfamide, and corticosteroids (Table 26.1).

Original languageEnglish
Title of host publicationThymus Gland Pathology: Clinical, Diagnostic, and Therapeutic Features
PublisherSpringer Milan
Number of pages4
ISBN (Print)9788847008274
Publication statusPublished - 2008

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Chemotherapy in thymic neoplasms'. Together they form a unique fingerprint.

Cite this